Patent intelligence · US
US 9550002
Phospholipid analogs as diapeutic agents and methods thereof
Phospholipid analogs as diapeutic agents and methods thereof
Patent details — US 9550002
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 24, 2017
- Expiration
- Jan 19, 2037
- Applicant
- CELLECTAR BIOSCIENCES, INC.
- Claims
- 34
- CPC classes
- A61K, A61K49/0017, A61K51/04, A61K51/0408
Quick answer
US 9550002 (Phospholipid analogs as diapeutic agents and methods thereof) is held by CELLECTAR BIOSCIENCES, INC.. Status: granted. Granted Jan 24, 2017. Expires Jan 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CELLECTAR BIOSCIENCES, INC.
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61K, A61K49/0017, A61K51/04, A61K51/0408, A61K51/0489, A61P
More from CELLECTAR BIOSCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 11439709
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9925269
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9616140
Fluorescent phospholipid ether compounds, compositions, and methods of use
granted -
US 9579406
Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
granted -
US 9480754
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9345718
Phospholipid ether analogs as cancer-targeting drug vehicles
granted
Related coverage
Frequently asked questions
What is US patent 9550002?
US 9550002 (Phospholipid analogs as diapeutic agents and methods thereof) is held by CELLECTAR BIOSCIENCES, INC.. Status: granted. Granted Jan 24, 2017. Expires Jan 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9550002?
CELLECTAR BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9550002 expire?
Our index shows an expiration date of Jan 19, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.